{
  "drug_name": "Azathioprine",
  "url": "https://wikem.org/wiki/Azathioprine",
  "scraped_at": "2026-01-10T07:48:26.901778",
  "sections": {
    "Administration": {
      "text": "Type: immunosuppressant\nDosage Forms: tablet, powder for injection (IV form unavailable in US)\nDosage Strengths: tablet: 50, 75, 100mg; powder for injection: 100mg/vial\nRoutes of Administration: PO, IV (unavailable in US)\nCommon Trade Names: Azasan, Imuran",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Kidney_transplant_rejection_prophylaxis": {
          "text": "1-3mg/kg PO QD\nStart: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary",
          "tables": []
        },
        "Rheumatoid_arthritis,_severe": {
          "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
          "tables": []
        },
        "Crohns_Disease": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects",
          "tables": []
        },
        "Ulcerative_colitis": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Kidney_transplant_rejection_prophylaxis": {
      "text": "1-3mg/kg PO QD\nStart: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary",
      "subsections": {
        "Rheumatoid_arthritis,_severe": {
          "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
          "tables": []
        },
        "Crohns_Disease": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects",
          "tables": []
        },
        "Ulcerative_colitis": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Rheumatoid_arthritis,_severe": {
      "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
      "subsections": {
        "Crohns_Disease": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects",
          "tables": []
        },
        "Ulcerative_colitis": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Crohns_Disease": {
      "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance and fistulizing disease, steroid-sparing effects",
      "subsections": {
        "Ulcerative_colitis": {
          "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Ulcerative_colitis": {
      "text": "100-250mg PO QD\nStart: 50mg PO QD; Max: 2.5mg/kg/day; Info: for induction or remission maintenance, steroid-sparing effects",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "Kidney_transplant_rejection_prophylaxis_2": {
          "text": "1-3mg/kg PO QD\nStart: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary",
          "tables": []
        },
        "Juvenile_idiopathic_arthritis,_severe": {
          "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Kidney_transplant_rejection_prophylaxis_2": {
      "text": "1-3mg/kg PO QD\nStart: 3-5mg/kg PO x1 up to 3 days before transplant; Info: transplant protocols may vary",
      "subsections": {
        "Juvenile_idiopathic_arthritis,_severe": {
          "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Juvenile_idiopathic_arthritis,_severe": {
      "text": "1-2.5mg/kg/day PO divided QD-bid\nStart: 1mg/kg/day PO divided QD-bid; Max: 2.5mg/kg/day; Info: after 6-8wk may increase 0.5mg/kg/day q4wk",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: Pregnancy Category D\nLactation risk\n: possibly unsafe",
      "subsections": {
        "Renal_Dosing": {
          "text": "Adult: CrCl 10-50: decrease dose 25%; CrCl <10: decrease dose 50%; HD: give 0.25mg/kg supplement; PD: not defined\nPediatric: CrCl 10-50: decrease dose 25% or give q36h; CrCl <10: decrease dose 50% or give q48h; HD: give supplement; PD: not defined",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "Adult: not defined; caution advised\nPediatric: not defined; caution advised",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "Adult: CrCl 10-50: decrease dose 25%; CrCl <10: decrease dose 50%; HD: give 0.25mg/kg supplement; PD: not defined\nPediatric: CrCl 10-50: decrease dose 25% or give q36h; CrCl <10: decrease dose 50% or give q48h; HD: give supplement; PD: not defined",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "Adult: not defined; caution advised\nPediatric: not defined; caution advised",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "Adult: not defined; caution advised\nPediatric: not defined; caution advised",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\npregnancy (RA use)\ncaution if renal impairment\ncaution if prior alkylating agents",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "leukopenia\nthrombocytopenia\nanemia\nmyelosuppression\nimmunosuppression\ninfection\nPML\nGI hypersensitivity reaction\npancreatitis\nhepatotoxicity\nhepatic veno-occlusive disease\nlymphoma\nmalignancy\nacute febrile neutrophilic dermatosis",
          "tables": []
        },
        "Common": {
          "text": "leukopenia\nthrombocytopenia\nanemia\ninfection\nnausea\nvomiting\nanorexia\ndiarrhea\nALT, AST elevated\nmalaise\nmyalgia\nfever\nrash\nmalignancy",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "leukopenia\nthrombocytopenia\nanemia\nmyelosuppression\nimmunosuppression\ninfection\nPML\nGI hypersensitivity reaction\npancreatitis\nhepatotoxicity\nhepatic veno-occlusive disease\nlymphoma\nmalignancy\nacute febrile neutrophilic dermatosis",
      "subsections": {
        "Common": {
          "text": "leukopenia\nthrombocytopenia\nanemia\ninfection\nnausea\nvomiting\nanorexia\ndiarrhea\nALT, AST elevated\nmalaise\nmyalgia\nfever\nrash\nmalignancy",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "leukopenia\nthrombocytopenia\nanemia\ninfection\nnausea\nvomiting\nanorexia\ndiarrhea\nALT, AST elevated\nmalaise\nmyalgia\nfever\nrash\nmalignancy",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 5 hours\nMetabolism: liver extensively, erythrocytes; CYP450\nExcretion: bile, urine (1-2% unchanged)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Acts as a prodrug for mercaptopurine, inhibiting an enzyme required for the synthesis of DNA. Thus, it most strongly affects proliferating cells, such as the T cells and B cells of the immune system",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Transplant complications",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Transplant complications",
          "url": "https://wikem.org/wiki/Transplant_complications"
        }
      ]
    },
    "References": {
      "text": "A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-1163. [PubMed 8229026]\nAmerican College of Rheumatology Ad Hoc Committee on Clinical Guidelines, “Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis,” Arthritis Rheum, 1996, 39(5):723-31. [PubMed 8639168]\nAstey AV, Wakelin S, and Reynolds NJ, “Guidelines for Prescribing Azathioprine in Dermatology,” Br J Dermatol, 2004, 151(6):1123-32. [PubMed 15606506]\nArmuzzi A, Felice C, Papa A, et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013;7(12):e623-e629. doi: 10.1016/j.crohns.2013.04.020. [PubMed 23810678]\nArnold DM, Nazi I, Santos A, et al, “Combination Immunosuppressant Therapy for Patients With Chronic Refractory Immune Thrombocytopenic Purpura,” Blood, 2010, 115(1):29-31. [PubMed 19897578]\nAronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 177.\nAzasan (azathioprine) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; March 2019.\nAzathioprine injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2015.\nBaum D, Bernstein D, Starnes VA, et al, “Pediatric Heart Transplantation at Stanford: Results of a 15-Year Experience,” Pediatrics, 1991, 88(2):203-14. [PubMed 1861916]\nBeissert S, Werfel T, Frieling U, et al, \"A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus,\" Arch Dermatol, 2006, 142(11):1447-54. [PubMed 17116835]\nepocrates",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}